Preview

Современная ревматология

Расширенный поиск

Перспективы использования тромбоцитарной плазмы в терапии ревматоидного артрита

https://doi.org/10.14412/1996-7012-2021-1-87-93

Аннотация

Представлен обзор данных литературы, посвященной механизмам действия богатой тромбоцитами плазмы (Platelet Rich Plasma, PRP) и опыту ее применения у пациентов с ревматоидным артритом (РА). Определено место PRP в системной и локальной терапии РА. Описаны химический состав PRP и структура включенных в нее органелл тромбоцитов. Дана оценка способов получения тромбоцитарной плазмы, содержащей различные концентрации ключевых факторов роста: тромбоцитарного фактора роста (PDGF), трансформирующего фактора роста α (TGFα), сосудистого эндотелиального фактора роста (VEGF), инсулиноподобного фактора роста (IGF) и эпидермального фактора роста (EGF). Рассмотрены варианты классификаций PRP, которые учитывают различия препаратов по составу и содержанию факторов роста. Проанализирован опыт внутрисуставного введения препаратов аутологичной плазмы пациентам с РА и синовитом. На основании приведенных данных сделано заключение о том, что PRP-терапия может оказаться эффективным инструментом купирования воспаления и стимуляции локальных процессов репарации поврежденных тканей сустава у больных РА. Дальнейшее изучение возможностей применения PRP-терапии и формирование ее протокола при РА позволят оказывать эффективную персонализированную помощь таким больным.

Об авторах

С. В. Маглеваный
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия

Сергей Владимирович Маглеваный

115522, Москва, Каширское шоссе, 34А

 



Е. А. Нарышкин
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия

115522, Москва, Каширское шоссе, 34А



Е. В. Четина
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия

115522, Москва, Каширское шоссе, 34А



М. А. Макаров
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия

115522, Москва, Каширское шоссе, 34А



Литература

1. Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматоидный артрит. В кн.: Насонов ЕЛ, Насонова ВА, редакторы. Ревматология. Национальное руководство. Москва: ГЭОТАР-Медиа; 2008. С. 290-331.

2. Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev. 2010 Jan;233(1):233- 55. doi: 10.1111/j.0105-2896.2009.00859.x.

3. Orr C, Vieira-Sousa E, Boyle DL, et al. Synovial tissue research: a state-of-the-art review. Nat Rev Rheumatol. 2017 Aug;13(8): 463-75. doi:10.1038/nrrheum.2017.115. Epub 2017 Jul 13.

4. Elshabrawy HA, Chen Z, Volin MV, et al. The pathogenic role of angiogenesis in rheumatoid arthritis. Angiogenesis. 2015 Oct; 18(4):433-48. doi: 10.1007/s10456-015-9477-2. Epub 2015 Jul 22.

5. Fang Q, Ou J, Nandakumar KS. Autoantibodies as Diagnostic Markers and Mediator of Joint Inflammation in Arthritis. Mediators Inflamm. 2019 Oct 27;2019: 6363086. doi: 10.1155/2019/6363086. eCollection 2019.

6. Monaco C, Nanchahal J, Taylor P, Feldmann M. Anti-TNF therapy: past, present and future. Int Immunol. 2015 Jan; 27(1):55-62. doi: 10.1093/intimm/dxu102. Epub 2014 Nov 19.

7. Насонов ЕЛ. Фармакотерапия ревматоидного артрита: новая стратегия, новые мишени. Научно-практическая ревматология. 2017;55(4):409-19.

8. Korhonen R, Moilanen E. Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis. Basic Clin Pharmacol Toxicol. 2009 Apr;104(4):276-84. doi: 10.1111/j.1742-7843.2009.00375.x. Epub 2009 Feb 18.

9. Dayer JM, Feige U, Edwards CK 3rd, et al. Anti-interleukin-1 therapy in rheumatic diseases. Curr Opin Rheumatol. 2001 May;13(3): 170-6. doi: 10.1097/00002281-200105000-00004.

10. Насонов ЕЛ. Новые направления фармакотерапии ревматических заболеваний – ингибиция интерлейкина 6 и интерлейкина 17. Современная ревматология. 2013; 7(3):5-14. doi: 10.14412/1996-7012-2013-04

11. Олюнин ЮА. Внутрисуставные инъекции лекарственных препаратов в комплексном лечении ревматических заболеваний. Современная ревматология. 2015;9(1):78–83. doi: 10.14412/1996-7012-2015-1-78-83

12. Af Klint E, Grundtman C, Engström M, et al. Intraarticular glucocorticoid treatment reduces inflammation in synovial cell infiltrations more efficiently than in synovial blood vessels. Arthritis Rheum. 2005 Dec;52(12): 3880-89. doi: 10.1002/art.21488

13. Gheorghe KR, Korotkova M, Catrina AI, et al. Expression of 5-lipoxygenase and 15-lipoxygenase in rheumatoid arthritis synovium and effects of intraarticular glucocorticoids. Arthritis Res Ther. 2009;11(3):R83. doi: 10.1186/ar2717. Epub 2009 Jun 4.

14. Nikas SN, Temekonidis TI, Zikou AK, et al. Treatment of resistant rheumatoid arthritis by intra-articular infliximab injections: a pilot study. Ann Rheum Dis. 2004 Jan;63(1):102-3. doi: 10.1136/ard.2003.006981

15. Zhang F, Ma C. Comparison of the effectiveness on intra-articular and subcutaneous TNF inhibitor in rheumatoid arthritis patients. Clin Rheumatol. 2018 Jan;37(1): 199-204. doi: 10.1007/s10067-017-3806-3. Epub 2017 Sep 4.

16. Mortada MA, Abdelwhab SM, Elgawish MH. Intra-articular methotrexate versus corticosteroid injections in medium-sized joints of rheumatoid arthritis patients-an intervention study. Clin Rheumatol. 2018 Feb; 37(2):331-7. doi: 10.1007/s10067-017-3843-y. Epub 2017 Sep 30.

17. Saito S, Kotake S. Is there evidence in support of the use of intra-articular hyaluronate in treating rheumatoid arthritis of the knee? A meta-analysis of the published literature. Mod Rheumatol. 2009;19(5):493-501. doi: 10.1007/s10165-009-0189-6. Epub 2009 Jun 23.

18. Васильев СА, Берковский АЛ, Мелкумян АЛ. Пособие по изучению функции тромбоцитов. Норма и патология. Москва; 2017. С. 9-12.

19. Lippi G, Franchini M. Platelets and immunity: the interplay of mean platelet volume in health and disease. Expert Rev Hematol. 2015 Oct;8(5):555-7. doi: 10.1586/17474086.2015.1069703. Epub 2015 Jul 15.

20. Nurden A. Platelets, inflammation and tissue regeneration. Thromb Haemost. 2011 May;105 Suppl 1:S13-33. doi: 10.1160/THS10-11-0720. Epub 2011 Apr 11.

21. Raposo G, Marks MS, Cutler DF. Lysosome-related organelles: driving postGolgi compartments into specialisation. Curr Opin Cell Biol. 2007 Aug;19:394-401 doi: 10.1016/j.ceb.2007.05.001. Epub 2007 Jul 12.

22. Ambrosio AL, Di Pietro SM. Storage pool diseases illuminate platelet dense granule biogenesis. Platelets. 2017 Mar;28(2):138- 146. doi: 10.1080/09537104.2016.1243789. Epub 2016 Nov 16.

23. Flaumenhaft R, Koseoglu S. Platelet Contents. In: Schulze H, Italiano J, editors. Molecular and Cellular Biology of Platelet Formation. Cham: Springer; 2016.

24. Scully D, Naseem KM, Matsakas A. Platelet biology in regenerative medicine of skeletal muscle. Acta Physiol (Oxf). 2018 Jul; 223(3):e13071. doi: 10.1111/apha.13071. Epub 2018 Apr 19.

25. Akhundov K, Pietramaggiori G, Waselle L, et al. Development of a cost-effective method for platelet-rich plasma (PRP) preparation for topical wound healing. Ann Burns Fire Disasters. 2012 Dec 31;25(4):207-13.

26. Oudelaar BW, Peerbooms JC, Huis In't Veld R, et al. Concentrations of blood components in commercial platelet-rich plasma separation systems: a review of the literature. Am J Sports Med. 2019 Feb;47(2):479-87. doi: 10.1177/0363546517746112. Epub 2018 Jan 16.

27. Samra DJ, Orchard JW. Patterns of platelet-rich plasma use among Australasian sports physicians. BMJ Open Sport Exerc Med. 2015 Nov 9;1(1):e000054. doi: 10.1136/bmjsem-2015-000054. eCollection 2015.

28. Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: From pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol. 2009 Mar; 27(3):158-67. doi: 10.1016/j.tibtech.2008.11.009. Epub 2009 Jan 31.

29. Magalon J, Chateau AL, Bertrand B, et al. DEPA classification: a proposal for standardising PRP use and a retrospective application of available devices. BMJ Open Sport Exerc. Med. 2016 Feb;2(1):e000060. doi: 10.1136/bmjsem-2015-000060. eCollection 2016.

30. Lana JFSD, Purita J, Paulus C, et al. Contributions for classification of platelet rich plasma - proposal of a new classification: MARSPILL. Regen Med. 2017 Jul;12(5): 565-74. doi: 10.2217/rme-2017-0042. Epub 2017 Jul 31.

31. Piao L, Park H, Jo CH. Theoretical prediction and validation of cell recovery rates in preparing platelet-rich plasma through a centrifugation. PLoS One. 2017 Nov 2;12(11): e0187509. doi: 10.1371/journal.pone.0187509. eCollection 2017.

32. Kushida S, Kakudo N, Morimoto N, et al. Platelet and growth factor concentrations in activated platelet-rich plasma: a comparison of seven commercial separation systems. J Artif Organs. 2014 Jun;17(2):186-92. doi: 10.1007/s10047-014-0761-5. Epub 2014 Apr 20.

33. Kameyoshi Y, Dö rschner A, Mallet AI, et al. Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med. 1992 Aug 1;176(2):587-92. doi: 10.1084/jem.176.2.587

34. Tohidnezhad M, Bayer A, Rasuo B, et al. Platelet-Released Growth Factors Modulate the Secretion of Cytokines in Synoviocytes under Inflammatory Joint Disease. Mediators Inflamm. 2017;2017:1046438. doi: 10.1155/2017/1046438. Epub 2017 Nov 19.

35. Passaretti F, Tia M, D'Esposito V, et al. Growth-promoting action and growth factor release by different platelet derivatives. Platelets. 2014;25(4):252-6. doi: 10.3109/09537104.2013.809060. Epub 2013 Jul 15.

36. Mishra A, Tummala P, King A, et al. Buffered platelet-rich plasma enhances mesenchymal stem cell proliferation and chondrogenic differentiation. Tissue Eng Part C Methods. 2009 Sep;15(3):431-5 doi: 10.1089/ten.tec.2008.0534

37. Krü ger JP, Hondke S, Endres M, et al. Human platelet-rich plasma stimulates migration and chondrogenic differentiation of human subchondral progenitor cells. J Orthop Res. 2012 Jun;30(6):845-52. doi: 10.1002/jor.22005. Epub 2011 Nov 4.

38. Cognasse F, Hamzeh-Cognasse H, Lafarge S, et al. Human platelets can activate peripheral blood B cells and increase production of immunoglobulins. Exp Hematol. 2007 Sep;35 (9):1376-87. doi: 10.1016/j.exphem.2007.05.021. Epub 2007 Jul 25.

39. Koupenova M, Clancy L, Corkrey HA, et al. Circulating platelets as mediators of immunity, inflammation, and thrombosis. Circ Res. 2018 Jan 19;122(2):337-51. doi: 10.1161/CIRCRESAHA.117.310795

40. Yeung J, Li W, Holinstat M. Platelet signaling and disease: targeted therapy for thrombosis and other related diseases. Pharmacol Rev. 2018 Jul;70(3):526-48. doi: 10.1124/pr.117.014530

41. Gasparyan AY, Ayvazyan L, Pretorius E. Platelets in rheumatic diseases: friend or foe? Curr Pharm Des. 2014;20(4):552-66. doi: 10.2174/138161282004140213143843.

42. Matsuno H. Remarkable efficacy of tocilizumab for treating rheumatoid arthritis in patients with high platelet counts. Mod Rheumatol. 2015 Jan;25(1):38-42. doi: 10.3109/14397595.2014.915073.

43. Zamora C, Canto E, Nieto JC, et al. Binding of Platelets to Lymphocytes: A Potential Anti-Inflammatory Therapy in Rheumatoid Arthritis. J Immunol. 2017 Apr 15;198(8):3099-108. doi: 10.4049/jimmunol.1601708. Epub 2017 Mar 1.

44. Gasparyan AY, Ayvazyan L, Mukanova U, et al. The Platelet-to-Lymphocyte Ratio as an Inflammatory Marker in Rheumatic Diseases. Ann Lab Med. 2019 Jul;39(4): 345-57. doi: 10.3343/alm.2019.39.4.345

45. Franck H, Rau R, Herborn G. Thrombocytopenia in patients with rheumatoid arthritis on long-term treatment with low dose methotrexate. Clin Rheumatol. 1996 May; 15(3):266-70. doi: 10.1007/BF02229705

46. Alsousou J, Thompson M, Harrison P, et al. Effect of platelet-rich plasma on healing tissues in acute ruptured Achilles tendon: a human immunohistochemistry study. Lancet. 2015 Feb 26;385 Suppl 1:S19. doi: 10.1016/S0140-6736(15)60334-8

47. Braun HJ, Wasterlain AS, Dragoo JL. The use of PRP in ligament and meniscal healing. Sports Med Arthrosc Rev. 2013 Dec; 21(4):206-12. doi: 10.1097/JSA.0000000000000005

48. Zhou Y, Wang JH. PRP Treatment Efficacy for Tendinopathy: A Review of Basic Science Studies. Biomed Res Int. 2016;2016: 9103792. doi: 10.1155/2016/9103792. Epub 2016 Aug 16.

49. Kim SJ, Yeo SM, Noh SJ, et al. Effect of platelet-rich plasma on the degenerative rotator cuff tendinopathy according to the compositions. J Orthop Surg Res. 2019 Dec;14(1): 408. doi: 10.1186/s13018-019-1406-4

50. Lim W, Park SH, Kim B, et al. Relationship of cytokine levels and clinical effect on platelet-rich plasma-treated lateral epicondylitis. J Orthop Res. 2018 Mar;36(3):913-20. doi: 10.1002/jor.23714. Epub 2017 Sep 20.

51. Shichao T, Ji L, Changqing Z. Plateletrich plasma inhibits inflammatory factors and represses rheumatoid fibroblast-like synoviocytes in rheumatoid arthritis. Clin Exp Med. 2017 Nov;17(4):441-9. doi: 10.1007/s10238-017-0449-2. Epub 2017 Jan 24.

52. Jin CH, Chae SY, Kim TH, et al. Effect of tumor necrosis factor-related apoptosisinducing ligand on the reduction of joint inflammation in experimental rheumatoid arthritis. J Pharmacol Exp Ther. 2010 Mar; 332(3):858-65. doi: 10.1124/jpet.109.159517. Epub 2009 Nov 20.

53. Yao Q, Seol DW, Mi Z, et al. Intra-articular injection of recombinant TRAIL induces synovial apoptosis and reduces inflammation in a rabbit knee model of arthritis. Arthritis Res Ther. 2006;8(1):R16. doi: 10.1186/ar1867.

54. Ichikawa K, Liu W, Fleck M, et al. TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis. J Immunol. 2003 Jul 15;171(2):1061-9. doi: 10.4049/jimmunol.171.2.1061

55. Chyuan IT, Tsai HF, Liao HJ, et al. An apoptosis-independent role of TRAIL in suppressing joint inflammation and inhibiting T-cell activation in inflammatory arthritis. Cell Mol Immunol. 2018 Sep;15(9):846-57. doi: 10.1038/cmi.2017.2. Epub 2017 Apr 10.

56. Lippross S, Moeller B, Haas H, et al. Intraarticular injection of platelet-rich plasma reduces inflammation in a pig model of rheumatoid arthritis of the knee joint. Arthritis Rheum. 2011 Nov;63(11):3344-53. doi: 10.1002/art.30547

57. Nadia A, Asmaa M. Anti-arthritic Effects of Platelets Rich Plasma and Hyaluronic Acid on Adjuvant-induced Arthritis in Rats. International Journal of Pharmacology. 2020;16:33-46; doi: 10.3923/ijp.2020.33.46

58. Badsha H, Harifi G, Murrell WD. Platelet Rich Plasma for Treatment of Rheumatoid Arthritis: Case Series and Review of Literature. Case Rep Rheumatol. 2020 Jan 31;2020:8761485. doi: 10.1155/2020/8761485. eCollection 2020.

59. Latalski M, Walczyk A, Fatyga M, et al. Allergic reaction to platelet-rich plasma (PRP): Case report. Medicine (Baltimore). 2019 Mar;98(10):e14702. doi: 10.1097/MD.0000000000014702

60. Shanshan Y, BinZhou Y, Chen S. Platelet-rich plasma promotes the migration and invasion of synovial fibroblasts in patients with rheumatoid arthritis. Mol Med Rep. 2016 Sep;14(3):2269-75. doi: 10.3892/mmr.2016.5500. Epub 2016 Jul 11.


Рецензия

Просмотров: 1003


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)